Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986043 | 0.96 | NR1H2 (0.39) | NR1H2SETD7GPR119USP2SMN1; SMN2 | |
| SCHEMBL3783647 | 0.89 | NR1H2 (0.39) | NR1H2SETD7GPR119USP2SMN1; SMN2 | |
| Bromide SCHEMBL6428393 | 0.81 | SETD7 (0.43) | NR1H2SETD7GPR119USP2SMN1; SMN2 | |
| SCHEMBL3315088 | 0.80 | NR1H2 (0.40) | NR1H2SETD7GPR119USP2SMN1; SMN2 | |
| SCHEMBL3319602 | 0.80 | NR1H2 (0.40) | NR1H2SETD7GPR119USP2SMN1; SMN2 | |
| SCHEMBL9282186 | 0.80 | SETD7 (0.43) | NR1H2SETD7GPR119USP2SMN1; SMN2 | |
| SCHEMBL15347416 | 0.78 | SLC6A9 (0.43) | NR1H2SETD7GPR119USP2SMN1; SMN2 | |
| SCHEMBL1673065 | 0.78 | SLC6A9 (0.43) | NR1H2SETD7GPR119USP2SMN1; SMN2 | |
| SCHEMBL17152994 | 0.78 | PLA2G10 (0.35) | — | |
| SCHEMBL13567937 | 0.78 | GPR119 (0.39) | NR1H2SETD7GPR119USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138332-B2 | Synthesis of cyclen derivatives | GE HEALTHCARE AS (NO) | 2012-03-20 | — | — | US | disclosed |
| EP-1877389-B1 | SYNTHESIS OF CYCLEN DERIVATIVES | GE HEALTHCARE AS (NO) | 2012-02-15 | — | — | EP | disclosed |
| US-20090216011-A1 | Synthesis of cyclen derivatives | AXELSSON OSKAR | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216011-A1 | Synthesis of cyclen derivatives | DCTN3, TET3, CCDC47 | NR1H2 4334/4885SETD7 1125/4885GPR119 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.